Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2005; 93(03): 618-619
DOI: 10.1055/s-0037-1616561
DOI: 10.1055/s-0037-1616561
Letters to the Editor
Nocturnal rise of urinary thromboxane B2 in patients with coronary artery disease
The study was carried out in the Division of IV Medical Clinic, University La Sapienza, Rome, Italy
Further Information
Publication History
Received
28 July 2004
Accepted after resubmission 30 December 2004
Publication Date:
14 December 2017 (online)
-
References
- 1 Muller JE, Toefler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79: 733-43.
- 2 Andreotti F, Davies GJ, Hackett DR et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death, and stroke. Am J Cardiol 1988; 62: 635-7.
- 3 Willich SN, Pohjola-Sintonen S, Bhatia SJS et al. Suppression of silent ischemia by metoprolol without alteration of morning increase of platelet aggregability in patients with stable coronary artery disease. Circulation 1987; 76: 488-91.
- 4 Tofler GH, Brezinski DA, Schafer A et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden death. N Engl J Med 1987; 316: 1514-8.
- 5 Brezinski DA, Tofler GH, Muller JE et al. Morning increase in platelet aggregability. Association with upright posture. Circulation 1988; 78: 35-40.
- 6 Ridker PM, Manson JE, Buring JE et al. Circadian variation of acute myocardial infarction and the effect of a low-dose aspirin in a randomised trial of physicians. Circulation 1990; 82: 897-902.
- 7 Patrono C, Patrignani P, Rocca B et al. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Thromb Haemost 1995; 74: 396-400.
- 8 Pradelles P, Grassi J, Maclouf J. Enzyme immunoassay of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 1985; 57: 1170-3.
- 9 Lellouch F, Fradin A, Fitzgerald GA. et al. Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin. Prostaglandins 1990; 40: 297-310.
- 10 Davì G, Gresele P, Violi F et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Circulation 1997; 96: 69-75.
- 11 Tohgi H, Konno S, Tamura K et al. Effects of lowto- high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992; 23: 1400-3.
- 12 Montalescot G, MacLouf J, Drobinski G et al. Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. J Am Coll Cardiol 1994; 24: 33-8.
- 13 Belton O, Byrne D, Kearney D et al. Cyclooxygenase- 1 and –2 dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-5.
- 14 Kearney D, Byrne A, Crean P et al. Optimal suppression of thromboxane A2 formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 2004; 43: 526-31.